Amplion
  • SOLUTIONS
    • MARKETING
    • SALES
    • BUSINESS DEVELOPMENT
  • WORKFLOWS
    • MARKETING
    • SALES
  • ABOUT
    • OUR DATA
    • WHY AMPLION?
    • CUSTOMER SUCCESS
  • TRIAL
  • GET A DEMO

  •  LOGIN
Select Page
European Emerging Pharma Orgs Advance Innovative Oncology Pipelines

European Emerging Pharma Orgs Advance Innovative Oncology Pipelines

Sep 26, 2023 | Emerging Biopharmas, News, Preclinical Research and Clinical Trials

Exciting oncology research is underway at several emerging European biopharmaceutical firms. Advances in cancer immunotherapies, antibody-drug conjugates, and combination therapies are highlighted in recent disclosures from these companies targeting both solid tumors...
Seed and Series A Biotech Funding: 2023

Seed and Series A Biotech Funding: 2023

Sep 21, 2023 | Basic Research and Discovery, Emerging Biopharmas, News, Preclinical Research and Clinical Trials, Therapeutic Areas

So far this year, Amplion has tracked 67 Seed and Series A investments into early-stage biotechs – down from 92 or a 27% decrease during the same period last year.  That said, the biotech sector continues to witness rapid advancements, with numerous early-stage...
Investigational New Drug Report: 2023

Investigational New Drug Report: 2023

Sep 11, 2023 | Emerging Biopharmas, News, Therapeutic Areas

The emerging pharmaceutical industry plays a vital role in developing innovative treatments and therapies for various diseases. In 2023, several emerging pharmaceutical companies have made significant strides towards advancing their drug programs across a range of...
Preclinical Advances in Cell Therapy in 2023

Preclinical Advances in Cell Therapy in 2023

Sep 6, 2023 | Emerging Biopharmas, News, Therapeutic Areas

Advances in Cell Therapy in 2023: A Year of Promising Preclinical Studies Cell therapy has emerged as a groundbreaking field in medical science, offering innovative solutions for a range of diseases and conditions that were previously considered challenging to treat....
Top 10 Emerging Biopharmas to Watch in 2023

Top 10 Emerging Biopharmas to Watch in 2023

Aug 30, 2023 | Emerging Biopharmas, News, Therapeutic Areas

A number of emerging biopharma companies have announced significant funding rounds in recent months, as investors continue to bet on the potential of these early-stage firms to develop new therapies for a variety of diseases. Here are some of the top deals, along with...
Precision Medicine Intelligence Platform
GET A DEMO
LOGIN

SOLUTIONS

Sales

Marketing

Business Development

RESOURCES

Life Science Lead Gen Guide

Marketing Workflows

Sales Workflows

Territory Sales Case Study

Global Sales Case Study

Research Pharma R&D

Life Science ABM Blog

COMPANY

Careers

Copyright 2023 SMG-Amplion    |     Terms & Conditions    |    Privacy Policy    |    GDPR Guidance

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT